Showing results (11-20 of 140) with videos related to
Sort By:
Pageof 14
Drugs in Context|August 18, 2018
Advances in the use of PARP inhibitor therapy for breast cancerKelly E McCann, Sara A HurvitzCancer|September 27, 2008
Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directionsSara A Hurvitz, Richard J PietrasFuture Oncology (London, England)|October 2, 2009
What's positive about 'triple-negative' breast cancer?Sara A Hurvitz, Richard S FinnTherapeutic Advances in Medical Oncology|October 25, 2014
Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potentialParvin F Peddi, Sara A HurvitzCurrent Opinion in Oncology|August 12, 2005
Current status of therapeutic vaccines for non-Hodgkin's lymphomaSara A Hurvitz, John M TimmermanFuture Oncology (London, England)|March 9, 2013
Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancerParvin F Peddi, Sara A HurvitzHematology/Oncology Clinics of North America|November 26, 2022
Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast CancerNicholas P McAndrew, Sara A HurvitzPharmacogenomics and Personalized Medicine|November 8, 2014
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansineSaeed Sadeghi, Olga Olevsky, Sara A HurvitzAnnals of Translational Medicine|January 9, 2015
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesDeborah J L Wong, Sara A HurvitzCancer Treatment Reviews|February 25, 2014
nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancerChristine Megerdichian, Yuliya Olimpiadi, Sara A HurvitzPageof 14